Capital International Inc. CA Sells 18,184 Shares of BeOne Medicines Ltd. – Sponsored ADR $ONC

Capital International Inc. CA cut its stake in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 5.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 307,660 shares of the company’s stock after selling 18,184 shares during the period. Capital International Inc. CA’s holdings in BeOne Medicines were worth $93,470,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Leonteq Securities AG bought a new stake in BeOne Medicines in the fourth quarter valued at approximately $35,000. Daiwa Securities Group Inc. bought a new stake in BeOne Medicines in the second quarter valued at approximately $35,000. CWM LLC boosted its holdings in BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after acquiring an additional 39 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in BeOne Medicines by 21.8% in the fourth quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock valued at $66,000 after acquiring an additional 39 shares during the last quarter. Finally, EverSource Wealth Advisors LLC bought a new stake in BeOne Medicines in the second quarter valued at approximately $68,000. 48.55% of the stock is currently owned by institutional investors.

BeOne Medicines Price Performance

BeOne Medicines stock opened at $270.10 on Friday. The stock has a market capitalization of $29.64 billion, a price-to-earnings ratio of 60.43 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $239.25 and a 52-week high of $385.22. The stock’s 50 day moving average price is $301.86 and its two-hundred day moving average price is $317.87. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The company had revenue of $1.51 billion for the quarter. On average, equities analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

Insider Transactions at BeOne Medicines

In other news, Director Corazon (Corsee) D. Sanders sold 212 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $309.59, for a total transaction of $65,633.08. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Alessandro Riva sold 212 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $309.51, for a total value of $65,616.12. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 1,641 shares of company stock valued at $505,791 over the last ninety days. Company insiders own 6.19% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on ONC shares. Leerink Partners upped their target price on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a report on Friday, May 15th. Wolfe Research initiated coverage on BeOne Medicines in a report on Friday, March 27th. They set an “outperform” rating and a $340.00 price target on the stock. Royal Bank Of Canada increased their price target on BeOne Medicines from $425.00 to $436.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, Jefferies Financial Group cut BeOne Medicines from a “buy” rating to a “hold” rating and cut their price target for the stock from $420.00 to $290.00 in a report on Monday, March 16th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $390.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.